Study proposes reconsidering how histone deacetylase inhibitors work in cancer treatment

Researchers at Baylor College of Medicine and collaborating institutions are challenging the traditional understanding of how cancer drugs called histone deacetylase (HDAC) inhibitors function. For decades, scientists believed that these drugs blocked HDAC enzymes, which drive cancer development by altering how genes are turned on and off.